Under the custom order scheme, rpsexdoll adopts a modular design (78% of modifiable parts) and stepped pricing. For the standard version (￥25,000), customers can select five appearance parameters (e.g., skin color ΔE value ±2, height ±3cm), the unit price of each additional function (e.g., temperature control module, dynamic expression) increases by 12-18%, and the premium configuration (e.g., AI interaction + full-joint customization) is priced at ￥128,000. 2023 figures show 34% of sales are generated through custom orders (industry average 15%), and the price per customer unit is now an average of ￥67,500 (standard model ￥38,000).
In terms of material choice flexibility, rpsexdoll offers 6 varieties of medical-grade silicone (Shaw hardness 00-50), 3 varieties of TPE composites (tensile strength 8-15MPa) and bespoke biocompatible gels (elastic modulus 0.03-0.08MPa). Lab tests have shown that hybrid material constructions (e.g., titanium alloy skeleton + silicone skin) enable product lifespan to be extended to up to 10 years (stock model 8 years), but it will cost 28% more. In the production order of a film and television company, to recover the body shape of ancient people (10cm height difference ±), the rate of material loss was reduced from the industry standard 12% to 4.5%, and 230,000 yuan of budget was saved.
In production cycle and delivery terms, simple custom orders are 45 days (30 days for normal models), and complicated customizations (e.g., bionic pupil dynamic tracking) up to 90 days. Based on digital twin technology (modeling error ≤0.1mm), its intelligent factory lowered the trial production defect rate from 3.2% to 0.8%, and the user acceptance rate has risen to 98%. A 2023 order by a customer in the Middle East for 100 units (for religious ceremonial use), from design confirmation through delivery within a mere 67 days (75 days contract cycle), saving logistic expenses by 19% (by modular packaging volume reduction by 32%).
Conformity to law is strict: rpsexdoll does not permit customization of physiological features in violation of ethics (e.g., over-exposed organs with an imitation grade of > 90%), and all models receive EU CE (EN 71-1/-2/-3) and ASTM F963-17 safety tests. In 2022, owing to refusal of a customer’s order for “surreal blood vessel texture” (which might lead to bioethical controversy), to avoid potential legal risks (penalty estimated at €500,000). Its blockchain document system is capable of tracing the 3D modeling data of each order (precision 0.01mm), and the judicial dispute rate is as low as 0.03% (industry 0.15%).
Customer cases reveal rpsexdoll rehabilitation assist model (range of joint movement ±150°) dedicated to medical centers has been undergoing FDA Class II certification, priced at a one-time fee of ￥189,000 (profit rate of 42%), and sales over 1,200 units annually. In another case, a co-branding luxury model (the decorative gold in inset is 18K gold due to the material specificity of 0.1mm±0.005 for gold layer thickness) had its yield reduced from 85% to 70%, but its premium rate reached 240% (price ￥298,000), but still made a net profit of ￥48 million.
For refund and modification policy, deposit is 30% (irrecoverable), extended to 70% upon confirmation of design. If the production error is beyond the range of the contract (e.g., ΔE of skin color > 3, deviation of size > 1cm), free reproduction is ensured (incidence rate 0.7%). In 2023, after the AI algorithm was upgraded, the matching degree between the design draft and final product increased from 92% to 99.5%, and the rate of after-sales modification decreased by 63%.
The facts indicate that rpsexdoll’s tailored policy has an industry leading-profit margin of 25% (15% average) with realization of individual demand (78% parts adjustable) under technical cost control (0.8% defect rate during trial production), legal risk management (zero rate of dispute) and modularity premium (34% of revenues). Its success stories are medicine, cinema, high-end luxury and other industries, rewriting the customization benchmark of the high-end bionic body market.